

# Nobumichi Tanaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2032464/publications.pdf>

Version: 2024-02-01

177  
papers

2,394  
citations

279798

23  
h-index

330143

37  
g-index

188  
all docs

188  
docs citations

188  
times ranked

3223  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy. <i>Supportive Care in Cancer</i> , 2022, 30, 887-895.	2.2	4
2	Videourodynamic effects of vibegron, a new selective $\beta_3$ -adrenoceptor agonist, on antimuscarinic-resistant neurogenic bladder dysfunction in patients with spina bifida. <i>International Journal of Urology</i> , 2022, 29, 76-81.	1.0	8
3	Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer. <i>Andrologia</i> , 2022, 54, e14288.	2.1	1
4	Usefulness of clinical factors for diagnosing and differentiating types of testicular malposition in boys: A retrospective study. <i>International Journal of Urology</i> , 2022, 29, 57-64.	1.0	4
5	Relevance of the perioperative edema index measured by bioelectrical impedance analysis for prediction of cardiovascular disease in living donor kidney transplantation. <i>International Journal of Urology</i> , 2022, , .	1.0	1
6	Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 196.e1-196.e9.	1.9	9
7	Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data. <i>Cancer Management and Research</i> , 2022, Volume 14, 623-635.	1.9	8
8	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study. <i>Cancers</i> , 2022, 14, 1735.	3.7	6
9	Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labelled, Randomized, Non-Placebo-Controlled Study. <i>Urology</i> , 2022, 161, 87-92.	1.0	1
10	Prostate diseases and microbiome in the prostate, gut, and urine. <i>Prostate International</i> , 2022, 10, 96-107.	2.3	25
11	5-Aminolevulinic acid overcomes hypoxia-induced radiation resistance by enhancing mitochondrial reactive oxygen species production in prostate cancer cells. <i>British Journal of Cancer</i> , 2022, 127, 350-363.	6.4	10
12	A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial. <i>Contemporary Clinical Trials Communications</i> , 2022, 26, 100902.	1.1	3
13	Editorial Comment on Ischemic proctitis after low-dose-rate brachytherapy using hydrogel spacer for prostate cancer. <i>IJU Case Reports</i> , 2022, 5, 241-241.	0.3	0
14	Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer. <i>Radiation Oncology</i> , 2022, 17, 71.	2.7	5
15	Association between urine 6-sulfatoxy-melatonin level and intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	0
16	Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2022, , .	0.5	0
17	Clinical impact of perioperative body fluid management in kidney transplant recipients. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 379-385.	0.1	0
18	Comparative effectiveness of low-dose-rate brachytherapy with or without external beam radiotherapy in favorable and unfavorable intermediate-risk prostate cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	4

#	ARTICLE	IF	CITATIONS
19	Sodium plays an important role in the absorption of intravesical fluid. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 177-182.	1.3	2
20	Photodynamic Diagnosis-Assisted En Bloc Transurethral Resection of Bladder Tumor for Nonmuscle Invasive Bladder Cancer: Short-Term Oncologic and Functional Outcomes. Journal of Endourology, 2021, 35, 319-327.	2.1	9
21	Trends in treatment outcomes for retractile testis in Japanese boys: A single-center study. International Journal of Urology, 2021, 28, 327-332.	1.0	5
22	External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. Journal of Bone Oncology, 2021, 26, 100344.	2.4	10
23	Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Science, 2021, 112, 1524-1533.	3.9	19
24	Fluorescent cystoscopy-assisted en bloc transurethral resection versus conventional transurethral resection in patients with non-muscle invasive bladder cancer: study protocol of a prospective, open-label, randomized control trial (the FLEBER study). Trials, 2021, 22, 136.	1.6	7
25	Effect of Prolonged Duration of Transrectal Ultrasound-Guided Biopsy of the Prostate and Pre-Procedure Anxiety on Pain in Patients without Anesthesia. Research and Reports in Urology, 2021, Volume 13, 111-120.	1.0	5
26	Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019. International Journal of Urology, 2021, 28, 720-726.	1.0	5
27	Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma. Research and Reports in Urology, 2021, Volume 13, 155-165.	1.0	1
28	Hexylaminolevulinic acid-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. BJU International, 2021, 128, 244-253.	2.5	7
29	The sustaining of fluorescence in photodynamic diagnosis after the administration of 5-aminolevulinic acid in carcinogen-induced bladder cancer orthotopic rat model and urothelial cancer cell lines. Photodiagnosis and Photodynamic Therapy, 2021, 34, 102309.	2.6	6
30	Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer. LUTS: Lower Urinary Tract Symptoms, 2021, , .	1.3	1
31	Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Science, 2021, 112, 3616-3626.	3.9	8
32	Long-term chronological changes in renal function and functional renal volume after nephron-sparing surgery: A prospective observational study. International Journal of Urology, 2021, 28, 1112-1119.	1.0	0
33	Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil. International Journal of Urology, 2021, 28, 1171-1176.	1.0	1
34	Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10,839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015. International Journal of Urology, 2021, 28, 1164-1170.	1.0	5
35	Assessment of bladder function for stabilizing urinary volume overnight with recording of brain waves ( ABSORB study). LUTS: Lower Urinary Tract Symptoms, 2021, , .	1.3	1
36	Clinical Impact of Subclinical Interstitial Fibrosis or Tubular Atrophy in 1-Hour Allograft Biopsy for Remnant Renal Function in Living Kidney Donors: A Prospective Observational Study. Transplantation Proceedings, 2021, 53, 2833-2840.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Remnant renal volume can predict prognosis of remnant renal function in kidney transplantation donors: a prospective observational study. <i>BMC Nephrology</i> , 2021, 22, 367.	1.8	5
38	Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer. <i>International Journal of Urology</i> , 2021, , .	1.0	2
39	Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems". <i>Quality of Life Research</i> , 2020, 29, 755-763.	3.1	2
40	Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 58-65.	1.3	3
41	Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. <i>International Journal of Urology</i> , 2020, 27, 17-23.	1.0	17
42	Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 54-61.	1.3	6
43	Rationale, design, and methods of electroencephalography-based investigation of the effects of oral desmopressin on improving slow-wave sleep time in nocturnal polyuria patients (the DISTINCT study): protocol for a single-arm, open-label, single-assignment trial. <i>BMC Urology</i> , 2020, 20, 96.	1.4	0
44	Role of Nuclear Claudin-4 in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8340.	4.1	12
45	Biochemical control of the combination of cyclooxygenase-2 inhibitor and 125 I brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial. <i>International Journal of Urology</i> , 2020, 27, 755-759.	1.0	2
46	Trends in treatment outcomes of hydrocele in Japanese children: A single-institute experience. <i>International Journal of Urology</i> , 2020, 27, 946-950.	1.0	2
47	Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study. <i>International Journal of Urology</i> , 2020, 27, 1013-1017.	1.0	2
48	Is Endoscopic Transurethral Incision Really Effective for Boys with Refractory Daytime Incontinence?. <i>Research and Reports in Urology</i> , 2020, Volume 12, 273-277.	1.0	0
49	Living-donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome. <i>IJU Case Reports</i> , 2020, 3, 244-247.	0.3	2
50	Evaluating the optimal technique of transperineal template-guided saturation biopsy in patients requiring repeat prostate biopsy. <i>International Journal of Urology</i> , 2020, 27, 1157-1158.	1.0	1
51	Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. <i>Diagnostics</i> , 2020, 10, 310.	2.6	38
52	Daily salt intake is associated with leg edema and nocturnal urinary volume in elderly men. <i>Neurourology and Urodynamics</i> , 2020, 39, 1550-1556.	1.5	3
53	Initial experience of complete laparoscopic radical nephroureterectomy combined with transvesical laparoscopic excision of distal ureter in patients with upper urinary tract cancer. <i>World Journal of Surgical Oncology</i> , 2020, 18, 104.	1.9	6
54	Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3789.	4.1	8

#	ARTICLE	IF	CITATIONS
55	Clinical Significance of Tumor Size, Pathological Invasion Sites Including Urinary Collecting System and Clinically Detected Renal Vein Thrombus as Predictors for Recurrence in pT3a Localized Renal Cell Carcinoma. <i>Diagnostics</i> , 2020, 10, 154.	2.6	9
56	A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study. <i>Contemporary Clinical Trials Communications</i> , 2020, 19, 100593.	1.1	1
57	Disabled Homolog 2 (DAB2) Protein in Tumor Microenvironment Correlates with Aggressive Phenotype in Human Urothelial Carcinoma of the Bladder. <i>Diagnostics</i> , 2020, 10, 54.	2.6	13
58	Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. <i>Chemotherapy</i> , 2020, 65, 1-6.	1.6	2
59	β-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer. <i>Oncology Letters</i> , 2020, 19, 2306-2316.	1.8	6
60	Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	9
61	Inhibitory Effect of Orally Administered 5-Aminolevulinic Acid on Prostate Carcinogenesis in the FVB-Transgenic Adenocarcinoma of a Mouse Prostate (FVB-TRAMP) Model. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3743-3749.	1.2	2
62	The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions. <i>Prostate International</i> , 2019, 7, 47-53.	2.3	11
63	Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-1 blockade decreases local recurrence after surgery in bladder cancer. <i>Cancer Science</i> , 2019, 110, 3315-3327.	3.9	17
64	Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis. <i>Neurourology and Urodynamics</i> , 2019, 38, 2311-2317.	1.5	7
65	Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2019, 11, 241-247.	1.3	7
66	Clinical Significance of Postoperative Nutritional Status as a Prognostic Factor in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2019, 51, 1763-1772.	0.6	4
67	A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future MRI-PDD Fusion TURBT™. <i>Diagnostics</i> , 2019, 9, 112.	2.6	4
68	Evaluation of Preoperative Abdominal Adipose Tissue, Inflammation-, Muscle Mass-, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors. <i>Transplantation Proceedings</i> , 2019, 51, 1706-1716.	0.6	4
69	Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS). <i>Brachytherapy</i> , 2019, 18, 484-492.	0.5	18
70	Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette-Guerin by the modulation of the tumor immune environment. <i>Oncology Reports</i> , 2019, 41, 1863-1874.	2.6	4
71	Localized prostate cancer with pelvic arteriovenous malformation treated with low-dose-rate brachytherapy after transcatheter embolization: Two case reports. <i>IJU Case Reports</i> , 2019, 2, 90-94.	0.3	1
72	Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin. <i>Diseases (Basel, Switzerland)</i> , 2019, 7, 44.	2.5	10

#	ARTICLE	IF	CITATIONS
73	Evaluation of pro- and anti-tumor effects induced by three colony-stimulating factors, G-CSF, GM-CSF and M-CSF, in bladder cancer cells: Is G-CSF a friend of bladder cancer cells?. <i>International Journal of Oncology</i> , 2019, 54, 2237-2249.	3.3	10
74	Docetaxel-based chemotherapy combined with dexamethasone 1Âmg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. <i>International Journal of Urology</i> , 2019, 26, 797-803.	1.0	8
75	Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. <i>Quality of Life Research</i> , 2019, 28, 2383-2391.	3.1	10
76	Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study. <i>International Journal of Urology</i> , 2019, 26, 630-637.	1.0	8
77	<i>Mycoplasma genitalium</i> Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens. <i>Cells</i> , 2019, 8, 212.	4.1	46
78	<p>Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume</p>. <i>Research and Reports in Urology</i> , 2019, Volume 11, 61-68.	1.0	5
79	Amrubicin is effective against small cell carcinoma of the prostate as a second-line chemotherapeutic agent: A case report. <i>IJU Case Reports</i> , 2019, 2, 133-136.	0.3	2
80	Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 4004-4010.	1.8	5
81	The diagnostic utility of retroperitoneoscopic tissue biopsy for unresectable retroperitoneal lesions excluding urogenital cancers. <i>World Journal of Surgical Oncology</i> , 2019, 17, 35.	1.9	4
82	Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2019, 11, 409-416.	0.9	5
83	Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer. <i>Journal of Radiation Research</i> , 2019, 60, 270-280.	1.6	8
84	Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 14, 51-58.	1.7	12
85	Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model. <i>Prostate</i> , 2019, 79, 340-351.	2.3	21
86	Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy. <i>International Journal of Clinical Oncology</i> , 2019, 24, 533-545.	2.2	33
87	A case in which colonic perforation occurred twice 10 years after cadaveric kidney transplantation. <i>Nihon Toseki Igakkai Zasshi</i> , 2019, 52, 551-557.	0.1	0
88	Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer. <i>Urology Journal</i> , 2019, 16, 145-151.	0.4	7
89	Unexpected presentation of allograft dysfunction triggered by page kidney phenomenon immediately after kidney transplantation: a case report. <i>BMC Nephrology</i> , 2018, 19, 59.	1.8	5
90	Clinical utility of bioelectrical impedance analysis in patients with locoregional muscle invasive or metastatic urothelial carcinoma: a subanalysis of changes in body composition during neoadjuvant systemic chemotherapy. <i>Supportive Care in Cancer</i> , 2018, 26, 1077-1086.	2.2	10



#	ARTICLE	IF	CITATIONS
91	Increased Urine Production Due to Leg Fluid Displacement Reduces Hours of Undisturbed Sleep. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 253-258.	1.3	7
92	Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. Neurourology and Urodynamics, 2018, 37, 666-672.	1.5	21
93	Successful salvage of allograft dysfunction triggered by transplant renal vein thrombosis immediately after kidney transplantation: a case report. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 321-327.	1.8	4
94	Quality of life worsened the most severely in patients immediately after intensity-modulated radiation therapy for prostate cancer. Research and Reports in Urology, 2018, Volume 10, 169-180.	1.0	2
95	Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy. Research and Reports in Urology, 2018, Volume 10, 103-111.	1.0	4
96	NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells. Cancers, 2018, 10, 347.	3.7	22
97	Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer. Cancer Investigation, 2018, 36, 395-405.	1.3	28
98	Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. International Journal of Clinical Oncology, 2018, 23, 1148-1159.	2.2	21
99	Overactive bladder induces transient hypertension. BMC Research Notes, 2018, 11, 196.	1.4	7
100	Spectrophotometric photodynamic diagnosis of prostate cancer cells excreted in voided urine using 5-aminolevulinic acid. Lasers in Medical Science, 2018, 33, 1557-1563.	2.1	5
101	Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide. BMC Research Notes, 2018, 11, 342.	1.4	2
102	Aquaporin-2 plays an important role in water transportation through the bladder wall in rats. Neurourology and Urodynamics, 2018, 37, 2434-2440.	1.5	11
103	Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer—A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor. Brachytherapy, 2018, 17, 537-543.	0.5	8
104	Impact of Preoperative Abdominal Visceral Adipose Tissue Area and Nutritional Status on Renal Function After Donor Nephrectomy in Japanese Living Donors for Renal Transplantation. Annals of Transplantation, 2018, 23, 364-376.	0.9	10
105	Gamma-Klotho exhibits multiple roles in tumor growth of human bladder cancer. Oncotarget, 2018, 9, 19508-19524.	1.8	21
106	A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. Anticancer Research, 2018, 38, 3097-3103.	1.1	13
107	Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study). Neurourology and Urodynamics, 2017, 36, 1097-1103.	1.5	11
108	Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus. Oncology Reports, 2017, 37, 227-234.	2.6	8

#	ARTICLE	IF	CITATIONS
109	Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database. <i>International Journal of Urology</i> , 2017, 24, 518-524.	1.0	12
110	The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 247-251.	1.3	12
111	Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2309-2316.	2.5	14
112	Diagnostic and prognostic role of urinary collagens in primary human bladder cancer. <i>Cancer Science</i> , 2017, 108, 2221-2228.	3.9	36
113	Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy. <i>Oncology</i> , 2017, 93, 259-269.	1.9	56
114	Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. <i>BMC Cancer</i> , 2017, 17, 237.	2.6	68
115	Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy. <i>BMC Urology</i> , 2017, 17, 28.	1.4	14
116	Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. <i>Oncotarget</i> , 2017, 8, 36099-36114.	1.8	76
117	Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2186.	4.1	71
118	Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 364-372.	0.9	2
119	Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitrosamine induced bladder cancer mouse model. <i>PLoS ONE</i> , 2017, 12, e0175494.	2.5	13
120	Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. <i>BMC Cancer</i> , 2017, 17, 573.	2.6	18
121	Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) – comparison between 2004–2006, 2007–2009, and 2010–2012. <i>BMC Cancer</i> , 2017, 17, 616.	2.6	12
122	Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. <i>BMC Cancer</i> , 2017, 17, 677.	2.6	15
123	Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. <i>BMC Urology</i> , 2017, 17, 62.	1.4	15
124	Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume. <i>Research and Reports in Urology</i> , 2017, Volume 9, 187-193.	1.0	8
125	Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer. <i>Molecular Carcinogenesis</i> , 2016, 55, 1378-1386.	2.7	39
126	Clinical significance of $\beta_1$ - and $\beta_2$ -Klotho in urothelial carcinoma of the bladder. <i>Oncology Reports</i> , 2016, 36, 2117-2125.	2.6	20



#	ARTICLE	IF	CITATIONS
127	Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 257.e11-257.e17.	1.6	44
128	Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients. <i>Brachytherapy</i> , 2016, 15, 736-745.	0.5	22
129	CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. <i>Neoplasia</i> , 2016, 18, 636-646.	5.3	161
130	Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial. <i>International Journal of Urology</i> , 2016, 23, 854-860.	1.0	10
131	Extended resection including adjacent organs and Ki-67 labeling index are prognostic factors in patients with retroperitoneal soft tissue sarcomas. <i>World Journal of Surgical Oncology</i> , 2016, 14, 43.	1.9	12
132	The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. <i>BMC Research Notes</i> , 2016, 9, 79.	1.4	15
133	Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 13, 225-232.	2.6	23
134	Non-ischemic, Non-renalorrhaphy Laparoscopic Partial Nephrectomy Using a Microwave Tissue Coagulator for Small Renal Tumors. <i>Journal of Microwave Surgery</i> , 2016, 34, 1-6.	0.3	2
135	A peritoneal dialysis patient with a right-sided aortic arch died of bronchial obstruction due to the enlargement of a Kommerell's diverticulum after laparoscopic nephrectomy for renal cell carcinoma. <i>Nihon Toseki Igakkai Zasshi</i> , 2016, 49, 247-252.	0.1	0
136	The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram. <i>BMC Research Notes</i> , 2015, 8, 689.	1.4	9
137	Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute. <i>International Journal of Urology</i> , 2015, 22, 541-547.	1.0	43
138	A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide. <i>Hormones and Cancer</i> , 2015, 6, 161-167.	4.9	6
139	Urethral toxicity after LDR brachytherapy: Experience in Japan. <i>Brachytherapy</i> , 2015, 14, 131-135.	0.5	11
140	Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2015, 12, 282-288.	2.6	22
141	Estimated functional renal parenchymal volume predicts the split renal function following renal surgery. <i>World Journal of Urology</i> , 2015, 33, 1571-1577.	2.2	18
142	Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. <i>BMC Cancer</i> , 2015, 15, 420.	2.6	4
143	Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 321-326.	0.6	12
144	Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 141-149.	0.8	35

#	ARTICLE	IF	CITATIONS
145	Review by urological pathologists improves the accuracy of Gleason grading by general pathologists. <i>BMC Urology</i> , 2015, 15, 70.	1.4	21
146	Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -. <i>Radiation Oncology</i> , 2014, 9, 302.	2.7	20
147	Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer. <i>Cancer Science</i> , 2014, 105, 616-622.	3.9	28
148	Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study. <i>Radiation Oncology</i> , 2014, 9, 208.	2.7	14
149	Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report. <i>BMC Research Notes</i> , 2014, 7, 760.	1.4	2
150	Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid. <i>BMC Urology</i> , 2014, 14, 59.	1.4	17
151	Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. <i>BMC Urology</i> , 2014, 14, 33.	1.4	49
152	Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume. <i>World Journal of Surgical Oncology</i> , 2014, 12, 59.	1.9	18
153	The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions. <i>Radiation Oncology</i> , 2014, 9, 107.	2.7	21
154	The Impact of Obstructive Sleep Apnea Syndrome on Nocturnal Urine Production in Older Men With Nocturia. <i>Urology</i> , 2014, 84, 892-897.	1.0	17
155	Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy. <i>Radiation Oncology</i> , 2013, 8, 25.	2.7	31
156	Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG) – a comparison between 2004-2006 and 2007-2009. <i>BMC Cancer</i> , 2013, 13, 588.	2.6	10
157	Immunohistochemical Analysis of Inflammatory Cells in Benign and Precancerous Lesions and Carcinoma of the Prostate. <i>Pathobiology</i> , 2013, 80, 119-126.	3.8	43
158	Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy. <i>Advances in Urology</i> , 2012, 2012, 1-7.	1.3	7
159	5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. <i>Oncology Letters</i> , 2012, 3, 1195-1202.	1.8	25
160	Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. <i>BMC Urology</i> , 2012, 12, 28.	1.4	11
161	Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection. <i>World Journal of Surgical Oncology</i> , 2012, 10, 249.	1.9	8
162	Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. <i>International Journal of Clinical Oncology</i> , 2011, 16, 553-559.	2.2	18

#	ARTICLE	IF	CITATIONS
163	The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-oncological research group registration. <i>BMC Urology</i> , 2011, 11, 6.	1.4	10
164	The Effects of Androgen Deprivation Therapy on Lipid Metabolism and Body Composition in Japanese Patients with Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 577-581.	1.3	31
165	Bone Scan Can Be Spared in Asymptomatic Prostate Cancer Patients with PSA of $\leq 20$ ng/ml and Gleason Score of $\leq 6$ at the Initial Stage of Diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1209-1213.	1.3	31
166	Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer. <i>Brachytherapy</i> , 2010, 9, 300-306.	0.5	18
167	Characteristics and management of erectile dysfunction after various treatments for prostate cancer. <i>International Journal of Urology</i> , 2010, 17, 689-697.	1.0	3
168	Trends of the Primary Therapy for Patients with Prostate Cancer in Nara Uro-oncological Research Group (NUORG): A Comparison Between the CaPSURE Data and the NUORG Data. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 588-592.	1.3	28
169	The surgical outcomes of non-ischemic partial nephrectomy using a microwave tissue coagulator for stage T1 renal cell carcinoma. <i>Journal of Microwave Surgery</i> , 2010, 28, 69-74.	0.3	0
170	Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: Our first series of 100 patients. <i>International Journal of Urology</i> , 2009, 16, 70-74.	1.0	11
171	Variations in International Prostate Symptom Scores, Uroflowmetric Parameters, and Prostate Volume After 125I Permanent Brachytherapy for Localized Prostate Cancer. <i>Urology</i> , 2009, 74, 407-411.	1.0	29
172	Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer. <i>Acta Urologica Japonica</i> , 2007, 53, 459-65.	0.1	5
173	Prediction of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma. <i>Urology</i> , 2004, 64, 904-908.	1.0	52
174	Non-ischemic Nephron-sparing Surgery for Small Renal Cell Carcinoma: Complete Tumor Enucleation Using a Microwave Tissue Coagulator. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, 95-102.	1.3	29
175	Comparison of serum levels of pyridinoline and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone resorption in patients receiving maintenance hemodialysis. <i>Clinical and Experimental Nephrology</i> , 1998, 2, 64-71.	1.6	0
176	Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma. <i>IJU Case Reports</i> , 0, , .	0.3	2
177	Efficacy of medical expulsive therapy using the traditional Japanese medicine (kampo) choreito for the spontaneous passage of proximal ureteric stones: A retrospective analysis. <i>Traditional &amp; Kampo Medicine</i> , 0, , .	0.6	0